Dr. Jim Xiang awarded a Saskatchewan Cancer Agency Grant

Dr. Jim Xiang was awarded a 2-year operating grant from the SCA for a project called: “Transgene 41BBL-engineered T cell-based vaccine stimulates potent therapeutic immunity against HER2-positive tumor in double transgenic HLA-A2/HER2 mice and trastuzumab-resistant BT474 breast cancer in humanized DKO/hHSC mice”.